Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cambridge Brain Mets Trial 1: A Proof-of-principle Phase 1b/Randomised Phase 2 Study of Afatinib Penetration Into Cerebral Metastases for Patients Undergoing Neurosurgical Resection, Both With and Without Prior Low-dose, Targeted Radiotherapy

NCT02768337 is registered in ClinicalTrials.gov with Cambridge University Hospitals NHS Foundation Trust as lead sponsor.

NCT NCT02768337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02768337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cambridge Brain Mets Trial 1: A Proof-of-principle Phase 1b/Randomised Phase 2 Study of Afatinib Penetration Into Cerebral Metastases for Patients Undergoing Neurosurgical Resection, Both With and Without Prior Low-dose, Targeted Radiotherapy
Lead sponsor
Cambridge University Hospitals NHS Foundation Trust
Phase
Phase 1/2
Overall status
Terminated
Start date
March 10, 2015
Completion date
August 12, 2021
Enrollment
26 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, advanced lung cancer, brain cancer, breast cancer, lung cancer